Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Façon, Thierry; Α. Dimopoulos, Meletios; Dispenzieri, Angela; Catalano, John; Belch, Andrew; Cavo, Michèle; Pinto, Antonello; Weisel, Katja; Ludwig, Heinz; J. Bahlis, Nizar; Banos, Anne; Tiab, Mourad; Delforge, Michel; Cavenagh, Jamie; Geraldes, Catarina; Lee, Je‐Jung; Chen, Christine; Oriol, Albert; de la Rubia, Javier; White, Darrell; Binder, Daniel; Lu, Jin; C. Anderson, Kenneth; Moreau, Philippe; Attal, Michel; Perrot, Aurore; Arnulf, Bertrand; Qiu, Lugui; Roussel, Murielle; M. Boyle, Eileen; Manier, Salomon; Mohty, Mohamad; Avet‐Loiseau, Hervé; Leleu, Xavier; Ervin‐Haynes, Annette; Chen, Guang; Houck, Vanessa; Benboubker, Lotfi; Hulin, Cyrille

doi:10.1182/blood-2017-07-795047

Public

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Published in Blood • Nov 17, 2017

Authors:

Thierry Façon

Meletios Α. Dimopoulos

Angela Dispenzieri

Abstract

= .0023), and similar with Rd18 (62.3 months). In patients achieving complete or very good partial responses, Rd continuous had an ≈30-month longer median time to next treatment vs Rd18 (69.5 vs 39.9 months). Over half of all patients who received second-line treatment were given a bortezomib-based ...

Subject

Multiple myeloma

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!